Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

公告精选 | 波司登中期营收同比增15.6%至53.89亿;信达生物:耐立克正式获国家药监局批准用于治疗慢性髓细胞白血病
Announcement selection | medium-term revenue of Bosideng International increased by 15.6% to 5.389 billion compared with the same period last year; INNOVENT BIO: Nellick was officially approved by the State Drug Administration for the treatment of chronic

富途資訊 ·  {{timeTz}}

重磅公告精选

A selection of blockbuster announcements

1、$先声药业(02096.HK)$:全球首个皮下注射PD-L1抗体恩沃利单抗注射液在中国获批上市

1、$Xiansheng Pharmaceutical Co., Ltd. (02096.HK) $The world's first subcutaneous injection of PD-L1 antibody Envoli monoclonal antibody injection has been approved for sale in China.

先声药业宣布,于2021年11月25日,集团与思路迪(北京)医药科技有限公司("思路迪(北京)医药")及江苏康宁杰瑞生物制药有限公司("江苏康宁杰瑞")合作的重组人源化PD-L1单域抗体Fc融合蛋白注射液恩维达®(通用名:恩沃利单抗注射液)获国家药品监督管理局("NMPA")附条件批准在中国上市,适用于不可切除或转移性微卫星高度不稳定(MSI-H)或错配修复基因缺陷型(dMMR)的成人晚期实体瘤患者的治疗,包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。

Xiansheng Pharmaceutical announced that on November 25, 2021 The group cooperates with Siludi (Beijing) Pharmaceutical Technology Co., Ltd. ("Siludi (Beijing) Pharmaceutical") and Jiangsu Kangning Jerry Biopharmaceutical Co., Ltd. ("Jiangsu Corning Jerry"). The recombinant humanized PD-L1 single-domain antibody Fc fusion protein injection (common name: Envoli monoclonal antibody injection) has been conditionally approved by the State Drug Administration ("NMPA") to be listed in China. It is suitable for the treatment of unresectable or metastatic microsatellite highly unstable (MSI-H) or mismatch repair gene deficiency (dMMR) adult advanced solid tumors, including advanced colorectal cancer patients who have progressed after previous treatment with fluorouracil, oxaliplatin and irinotecan, as well as other advanced solid tumors who have progressed after previous treatment and have no satisfactory alternative treatment.

2、$微创机器人-B(02252.HK)$:R-One™血管介入手术机器人完成NMPA注册临床试验首例入组

2、$minimally invasive robot-B (02252.HK) $R-One vascular interventional surgery robot completes NMPA registration clinical trial: the first case in the group

微创机器人公告,公司和法国Robocath S.A.S联合在华成立的合资公司知脉(上海)机器人有限公司(以下简称"知脉")引进的R-One™血管介入手术机器人完成了在中国的首例机器人辅助经皮冠状动脉介入治疗。这是R-One™完成的国家药品监督管理局("NMPA")注册临床试验首例入组手术,也标志着公司在血管介入行业内的又一新的里程碑。

Minimally invasive robot announcement, the company and the French Robocath S.A.S joint venture Zhimai (Shanghai) Robot Co., Ltd. (hereinafter referred to as "Zhimai") introduced R-One vascular interventional surgery robot to complete the first robot-assisted percutaneous coronary intervention in China. This is the first enrollment of a clinical trial registered by the State Drug Administration ("NMPA") completed by R-One drugs and marks a new milestone for the company in the vascular intervention industry.

3、$招商银行(03968.HK)$:获准发行不超430亿元无固定期限资本债券

3、$China Merchants Bank (03968.HK) $Approved to issue open-ended capital bonds of not more than 43 billion yuan

招商银行发布公告,招商银行已收到《中国银保监会关于招商银行发行无固定期限资本债券的批复》(银保监复〔2021〕838号)和《中国人民银行准予行政许可决定书》(银许准予决字〔2021〕第184号),同意该公司在全国银行间债券市场发行不超过430亿元人民币无固定期限资本债券。

China Merchants Bank issued an announcement, China Merchants Bank has received the approval of the China Banking and Insurance Regulatory Commission on China Merchants Bank's issuance of open-ended capital bonds (Bancassurance Supervision reply (2021) No. 838) and the decision of the people's Bank of China to grant administrative license (Bank of China grant decision (2021) No. 184). It is agreed that the company will issue no more than 43 billion yuan of open-ended capital bonds in the national interbank bond market.

4、$波司登(03998.HK)$:中期营收同比增长15.6%至53.89亿

4、$Bosideng International (03998.HK) $Medium-term revenue increased by 15.6% year-on-year to 5.389 billion

波司登公告,截至2021年9月30日止6个月,公司收入增加15.6%至约人民币53.9亿元,期间毛利率提升2.7个百分点至50.5%,经营溢利率提升0.5个百分点至14.8%,公司权益股东应占溢利上升31.4%至约人民币6.4亿元,董事会宣派中期股息每股普通股4.5港仙。期间品牌羽绒服业务仍为集团的最大收入来源,录得收入约为人民币34.73亿元,占总收入的64.5%,同比上升16.2%;贴牌加工管理业务录得收入约为人民币14.28亿元,占总收入的26.5%,同比增长16.2%;多元化服装业务录得收入约为人民币7180万元,占总收入的1.3%,同比上升129.2%。

Bosideng International announced that in the six months ended September 30, 2021, the company's revenue increased by 15.6% to about RMB 5.39 billion, gross profit margin increased by 2.7% to 50.5%, and operating profit increased by 0.5% to 14.8%. The profit attributable to the company's equity shareholders rose by 31.4% to about 640 million yuan, and the board of directors declared an interim dividend of HK4.5 cents per common share. During the period, the brand down jacket business remained the largest source of income for the group, with revenue of about 3.473 billion yuan, accounting for 64.5% of the total income, up 16.2% from the same period last year. The income recorded by the OEM processing management business was about 1.428 billion yuan, accounting for 26.5% of the total income, an increase of 16.2% over the same period last year. The diversified clothing business recorded revenue of about 71.8 million yuan, accounting for 1.3% of the total revenue, up 129.2% from a year earlier.

5、$阿里影业(01060.HK)$:上半年实现营13.58亿元,经调整EBITA为亏损约人民币0.05亿元

5、BABA Pictures (01060.HK) $In the first half of the year, the camp realized 1.358 billion yuan, and the adjusted EBITA was a loss of about 5 million yuan.

阿里影业公布9月止六个月中期业绩,上半年收入录得13.58亿人民币(下同),按年增加46.6%。上半年每股亏损0.2元,去年同期亏损0.61元。上半年经调整EBITA为亏损约人民币0.05亿元,接近盈亏平衡,对比过往期间亏损约人民币1.04亿元,亏损大幅收窄人民币近1亿元。不派中期息。

BABA Pictures announced interim results for the six months ended September, with revenue of 1.358 billion yuan in the first half (the same below), an annual increase of 46.6 percent. The loss per share was 0.2 yuan in the first half of the year and 0.61 yuan in the same period last year. The adjusted EBITA for the first half of the year is about RMB 5 million, which is close to the break-even point. Compared with the previous period, the loss is about RMB 104 million, and the loss is significantly narrowed by nearly RMB 100m. No interim interest.

6、$花样年控股(01777.HK)$:附属公司花样年投资因贷款问题被申请清盘

6、In the mood for the year Holdings (01777.HK) $The subsidiary company in the mood for investment was applied for winding up due to loan problems

花样年控股联交所公告,11月24日,本公司主要附属公司花样年投资被申请清盘呈请,内容有关据称未偿还本金为1.49亿美元贷款融资,花样年投资为担保人。本公司将寻求法律意见以维护其合法权益,并采取一切必要措施解决此事,包括与呈请人进行建设性的对话。本公司将适时刊发进一步公告。

On November 24th, the principal subsidiary of the Company was filed for winding-up petition relating to the alleged outstanding principal of US $149 million loan financing, with pattern year Investment as the guarantor. The company will seek legal advice to safeguard its legitimate rights and interests and take all necessary measures to resolve the matter, including a constructive dialogue with the petitioner. Our company will issue a further announcement in due course.

新股动向

Trend of new shares

微创机器人-B(02252):稳定价格行动及稳定价格期间结束

Minimally invasive Robot-B (02252): price stabilization action and end of price stabilization period

重大事项

Important matters

花样年控股(01777):附属公司花样年投资因贷款问题被申请清盘

Pattern year Holdings (01777): the subsidiary's pattern year Investment is applied for winding up due to loan problems.

中远海运港口(01199):招商局港口等各方签署合资经营协议和章程

Cosco Marine Port (01199): China Merchants Port and other parties signed joint venture agreements and articles of association

中国交通建设(01800):4家子公司拟以增资扩股还债模式开展债转股业务,引进投资者合计增资不超过75亿元

China Communications Construction (01800): four subsidiaries plan to carry out debt-to-equity swap business by increasing capital, expanding shares and repaying debts, bringing in investors with a total capital increase of no more than 7.5 billion yuan.

中国交通建设(01800):拟设立全资子公司中国交建利比里亚有限公司

China Communications Construction (01800): China Communications and Construction Liberia Co., Ltd., a wholly-owned subsidiary to be established.

中国燃气(00384):与维多集团订立战略合作协议,共同拓展中国LNG贸易市场

China Gas (00384): enter into a strategic cooperation agreement with Victoria Group to jointly expand China's LNG trade market.

微创机器人-B(02252):合资引进R-One™血管介入手术机器人完成在中国首例机器人辅助经皮冠状动脉介入治疗(PCI)

Minimally invasive Robot-B (02252): the first robot-assisted percutaneous coronary intervention (PCI) in China was completed with the introduction of a joint venture R-One vessel interventional surgery robot.

亚盛医药-B(06855):原创1类新药奥雷巴替尼片正式获中国国家药品监督管理局(NMPA)上市批准

Yasheng Pharmaceutical-B (06855): the original Class 1 new drug Orebatinib tablets is officially approved by the State Drug Administration (NMPA) of China.

康宁杰瑞制药-B(09966):KN035(恩沃利单抗注射液)获得国家药监局在中国的上市批准

Corning Jerry Pharmaceutical-B (09966): KN035 (Envoli Monoclonal Antibody injection) is approved by the State Drug Administration for listing in China.

先声药业(02096):KN035(恩沃利单抗注射液)获得国家药监局在中国的上市批准

Xiansheng Pharmaceutical (02096): KN035 (Envoli Monoclonal Antibody injection) is approved by the State Drug Administration for listing in China.

四环医药(00460):轩竹生物吡罗西尼(与芳香化酶抑制剂联合治疗)获批开展三期临床试验

Sihuan Medicine (00460): Xuan bamboo biological pyrrosinil (combined with aromatase inhibitor) is approved to conduct phase III clinical trials

上海医药(02607):旗下氯氮平片通过仿制药一致性评价

Shanghai Pharmaceutical (02607): evaluation of the consistency of clozapine tablets through generic drugs

山东新华制药股份(00719):2021年A股股票期权激励计划获华鲁控股批复

Shandong Xinhua Pharmaceutical Co., Ltd. (00719): 2021 A-share Stock option incentive Plan approved by Hualu Holdings

信达生物(01801):耐立克®正式获国家药监局批准用于治疗慢性髓细胞白血病

INNOVENT BIO (01801): Nerek ®is officially approved by the State Drug Administration for the treatment of chronic myeloid leukemia.

三叶草生物-B(02197):COVID-19候选疫苗在研究人员主导的II期临床试验中作为异源加强剂给药

Clover bio-B _ (02197): COVID-19 candidate vaccine is administered as a heterologous enhancer in phase II clinical trials led by researchers.

  • 财报数据

  • Financial report data

李氏大药厂(00950):前三季纯利21.69亿港元,同比增长1677.8%

Li Da Pharmaceutical Co., Ltd. (00950): net profit in the first three quarters was HK $2.169 billion, an increase of 1677.8% over the same period last year.

阿里影业(01060):中期收入大幅增长47%至13.58亿元

BABA Pictures (01060): medium-term income increased by 47% to 1.358 billion yuan

波司登(03998):中期股东应占溢利上升31.4%至约6.385亿元,每股派4.5港仙

Bosideng International (03998): medium-term profit attributable to shareholders increased by 31.4% to about 638.5 million yuan, or HK4.5 cents per share

北控清洁能源集团(01250):10月完成发电量约35.96万兆瓦时,同比增长13.8%

Beijing Control Clean Energy Group (01250): generating capacity of about 359600 MW hours was completed in October, an increase of 13.8% over the same period last year.

  • 股权激励

  • Equity incentive

康宁杰瑞制药-B(09966):11月25日授出111.34万股奖励股份

Corning Jerry Pharmaceutical-B (09966): awarded 1.1134 million award shares on November 25th

  • 回购注销

  • Repurchase cancellation

汇丰控股(00005):11月24日回购155.28万股

HSBC Holdings PLC (00005): buy back 1.5528 million shares on November 24th

汇丰控股(00005):11月25日回购388.14万股

HSBC Holdings PLC (00005): buy back 3.8814 million shares on November 25th

编辑/irisz

Edit / irisz

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top